KR900009080A - 골수 억제제 - Google Patents
골수 억제제 Download PDFInfo
- Publication number
- KR900009080A KR900009080A KR1019890016866A KR890016866A KR900009080A KR 900009080 A KR900009080 A KR 900009080A KR 1019890016866 A KR1019890016866 A KR 1019890016866A KR 890016866 A KR890016866 A KR 890016866A KR 900009080 A KR900009080 A KR 900009080A
- Authority
- KR
- South Korea
- Prior art keywords
- radionuclide
- composition
- bone marrow
- holmium
- samarium
- Prior art date
Links
- 210000001185 bone marrow Anatomy 0.000 title claims 5
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 5
- UIWYJDYFSGRHKR-NJFSPNSNSA-N gadolinium-159 Chemical compound [159Gd] UIWYJDYFSGRHKR-NJFSPNSNSA-N 0.000 claims 4
- KJZYNXUDTRRSPN-OUBTZVSYSA-N holmium-166 Chemical compound [166Ho] KJZYNXUDTRRSPN-OUBTZVSYSA-N 0.000 claims 4
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims 4
- 230000001629 suppression Effects 0.000 claims 4
- 206010065553 Bone marrow failure Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical group C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000003039 myelosuppressive effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000011285 therapeutic regimen Methods 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- JDZNTUQRMDAIRO-UHFFFAOYSA-N dimethylmyleran Chemical group CS(=O)(=O)OC(C)CCC(C)OS(C)(=O)=O JDZNTUQRMDAIRO-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (20)
1,4,7,10-테트라아자시클로도데칸 잔기를 함유하는 하나 이상의 거대환상 아미노포스폰산 리간드(여기에서, 포스폰산 작용기는 알킬렌 그룹을 통해 기대환상 폴리아민의 질소에 부착되어 있다) 또는 생리학적으로 허용되는 그의 염과 착화된, 사마륨-153, 가돌리늄-159, 홀뮴-166 또는 이트륨-90으로부터 선택된 하나이상의 방사성핵종을 포함하는 하나 이상의 골수억제 조성물 골수억제량을 골수억제 치료가 필요한 포유동물에게 투여함을 포함하는 골수억제 방법.
제1항에 있어서, 리간드가 1,4,7,10-테트라아자시클로도데칸테트라 메틸렌포스폰산 또는 그의 생리학적으로 허용되는 염인 골수억제 방법.
제1항 또는 제2항에 있어서, 방사성 핵종이 사마륨-153인 골수억제 방법.
제1항 또는 제2항에 있어서, 방사성 핵종이 가돌리늄-159인 골수억제 방법.
제1항 또는 제2항에 있어서, 방사성 핵종이 홀뮴-166인 골수억제 방법.
제1항 또는 제2항에 있어서, 방사성 핵종이 이트륨-90인 골수억제 방법.
제1항 내지 6항중 어느 한 항에 있어서, 백혈병, 임파종, 골수종 또는 호지킨병의 치료를 위해 하나 이상의 치료적 양생법과 함께 사용되는 골수억제 방법.
제1항 내지 7항중 어느 한 항에 있어서, (a) 하나 이상의 골수억체제, 및/또는 (b) 하나 이상의 화학요법제, 및/또는 (c) 하나 이상의 방사성치료제 또는 방사상 치료방법 중 적어도 하나를 사용하는 추가 치료 양생법과 함께 사용되는 골수억제 방법.
제8항에 있어서, 전신방사 또는 표적에 맞춘 외적 방사와 함께 사용된 골수억제 방법.
제8항 또는 제9항에 있어서, 적어도 하나의 화학요법제를 사용하는 치료법과 함께 사용된 골수억제 방법.
제10항에 있어서, 화학요법제가 디메틸 부술판, 시클로포스파미드, 비스클로로에틸 니트로소우레아, 시토신 아라비노시드 또는 6-티오구아닌 인 골수억제 방법.
제1항 내지 11항중 어느 한 항에 있어서, 충분한 골수억제를 이룩한후 골수이색의 추가단계를 포함하는 골수억제 방법.
1,4,7,10-테트라아자시클로도데칸 잔기를 함유하는 하나 이상의 거대환상 아미노포스폰산 리간드 또는 생리학적으로 허용되는 그의 염과 착화된, 사마륨-153, 가돌리늄-159, 홀뮴-166 또는 이트륨-90 으로부터 선택된 하나 이상의 방사성핵종을 포함하는, 골수억제를 위해 포유동물에게 투여하기에 적합한 멸균 조성물(여기에서, 상기 리간드의 인은 알킬렌 잔기를 통해 아민의 질소에 부착되어 있고, 투약 형태에서 상기 방사성 핵종은 상기 포유동물의 몸무게 ㎏당 18 내지 1850 메가벡쿼렐을 함유하는 양으로 존재한다.
제13항에 있어서, 투약 형태가 상기 포유동물의 몸부게 ㎏당 185 내지 1850 메가벡쿼렐을 함유하는 조성물.
제13항 또는 제14항에 있어서, 방사성핵종이 사마륨-153인 조성물.
제13항 또는 제14항에 있어서, 방사성핵종이 가돌리늄-159인 조성물.
제13항 또는 제14항에 있어서, 방사성핵종이 홀뮴-166인 조성물.
제13항 또는 제14항에 있어서, 방사성핵종이 이트륨-90인 조성물.
제13항 내지 18항 중 어느 한 항에 있어서 리간드 대 방사성 핵종의 비가 1:1 내지 2:1인 조성물.
약학적으로 허용되는 담체에 제13항 내지 제19항중 어느 한 항에서 특허청구된 조성물을 포함하는 약학제제.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US284,875 | 1988-12-19 | ||
US07/284,875 US4882142A (en) | 1988-12-19 | 1988-12-19 | Bone marrow suppressing agents |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900009080A true KR900009080A (ko) | 1990-07-02 |
KR0142907B1 KR0142907B1 (ko) | 1998-07-15 |
Family
ID=23091850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890016866A KR0142907B1 (ko) | 1988-12-19 | 1989-11-21 | 골수억제제 |
Country Status (17)
Country | Link |
---|---|
US (1) | US4882142A (ko) |
EP (1) | EP0374501B1 (ko) |
JP (1) | JP2795934B2 (ko) |
KR (1) | KR0142907B1 (ko) |
AT (1) | ATE92339T1 (ko) |
AU (1) | AU625644B2 (ko) |
CA (1) | CA2003326C (ko) |
DE (1) | DE68908125T2 (ko) |
DK (1) | DK175607B1 (ko) |
FI (1) | FI895516A0 (ko) |
HK (1) | HK152395A (ko) |
IE (1) | IE69049B1 (ko) |
IL (1) | IL92373A (ko) |
NZ (1) | NZ231474A (ko) |
PH (1) | PH26086A (ko) |
PT (1) | PT92362B (ko) |
ZA (1) | ZA898866B (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5064633A (en) * | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
US5059412A (en) * | 1984-06-04 | 1991-10-22 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors |
US4976950A (en) * | 1988-12-19 | 1990-12-11 | The Dow Chemical Company | Bone marrow suppressing agents |
WO1991016075A1 (en) * | 1990-04-20 | 1991-10-31 | Australian Nuclear Science & Technology Organisation | Bone marrow treatments |
MC2260A1 (fr) * | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
US5133956A (en) * | 1991-05-30 | 1992-07-28 | The Dow Chemical Company | Radiolabeled metal-binding protein for the treatment of arthritis |
US5320829A (en) * | 1991-12-10 | 1994-06-14 | The Dow Chemical Company | Oral compositions for inhibiting plaque formation |
DK2255800T3 (da) * | 1997-11-10 | 2013-02-04 | Sloan Kettering Inst Cancer | Arsentrioxid til anvendelse ved behandling af leukæmi |
AU2652599A (en) * | 1998-01-06 | 1999-07-26 | University Of Virginia Patent Foundation | Nuclear scintigraphic assessment of mucosal function |
US7205404B1 (en) * | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
EP1191948A2 (en) * | 1999-06-11 | 2002-04-03 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
US7094885B2 (en) * | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
US6794371B1 (en) * | 1999-10-18 | 2004-09-21 | The Dow Chemical Company | Aminoalkylenephosphonates for treatment of bone disorders |
US6565828B2 (en) * | 2000-04-07 | 2003-05-20 | Bristol-Myers Squibb Company | Macrocyclic chelants for metallopharmaceuticals |
NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
US6440389B1 (en) * | 2000-07-19 | 2002-08-27 | The General Hospital Corporation | Fluorescent agents for real-time measurement of organ function |
AU2002249935A1 (en) | 2001-01-08 | 2002-08-19 | Neorx Corporation | Radioactively labelled conjugates of phosphonates |
US6776977B2 (en) | 2001-01-09 | 2004-08-17 | Bristol-Myers Squibb Pharma Company | Polypodal chelants for metallopharmaceuticals |
US20030215391A1 (en) * | 2001-07-19 | 2003-11-20 | Carlos Rabito | Fluorescent agents for real-time measurement of organ function |
WO2003051403A1 (en) | 2001-12-13 | 2003-06-26 | Dow Global Technologies Inc. | Treatment of osteomyelitis with radiopharmaceuticals |
US20030228256A1 (en) * | 2002-06-11 | 2003-12-11 | Inverardi Luca A. | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations |
WO2004052408A1 (en) * | 2002-12-10 | 2004-06-24 | University Of Miami | Radioablation of hemolymphopoietic cell populations |
WO2007126730A1 (en) * | 2006-03-29 | 2007-11-08 | Isotherapeautics Group Llc | Radionuclide therapy for urinary bladder cancer |
HUE062439T2 (hu) | 2013-10-07 | 2023-11-28 | Igl Pharma Inc | Eljárás nagy tisztaságú terápiás csont szerek elõállítására |
CN114404427A (zh) | 2014-02-13 | 2022-04-29 | 配体药物公司 | 前药化合物及其用途 |
US9994600B2 (en) | 2014-07-02 | 2018-06-12 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
EP3302496B1 (en) * | 2015-05-25 | 2021-01-06 | IGL Pharma, Inc. | Dotmp kit formulations for radioisotopes |
EP3737676B1 (en) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4508625A (en) * | 1982-10-18 | 1985-04-02 | Graham Marshall D | Magnetic separation using chelated magnetic ions |
IL74902A (en) * | 1984-06-04 | 1990-12-23 | Dow Chemical Co | Organic amine phosphonic acid complexes with particle-emitting radionuclides for the treatment of calcific tumors |
US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
-
1988
- 1988-12-19 US US07/284,875 patent/US4882142A/en not_active Expired - Lifetime
-
1989
- 1989-11-20 DK DK198905827A patent/DK175607B1/da not_active IP Right Cessation
- 1989-11-20 FI FI895516A patent/FI895516A0/fi not_active Application Discontinuation
- 1989-11-20 CA CA002003326A patent/CA2003326C/en not_active Expired - Lifetime
- 1989-11-20 IL IL9237389A patent/IL92373A/en not_active IP Right Cessation
- 1989-11-21 DE DE89121564T patent/DE68908125T2/de not_active Expired - Lifetime
- 1989-11-21 KR KR1019890016866A patent/KR0142907B1/ko not_active IP Right Cessation
- 1989-11-21 PH PH39563A patent/PH26086A/en unknown
- 1989-11-21 PT PT92362A patent/PT92362B/pt not_active IP Right Cessation
- 1989-11-21 AT AT89121564T patent/ATE92339T1/de not_active IP Right Cessation
- 1989-11-21 EP EP89121564A patent/EP0374501B1/en not_active Expired - Lifetime
- 1989-11-21 ZA ZA898866A patent/ZA898866B/xx unknown
- 1989-11-21 IE IE371489A patent/IE69049B1/en not_active IP Right Cessation
- 1989-11-21 JP JP1300943A patent/JP2795934B2/ja not_active Expired - Fee Related
- 1989-11-22 AU AU45440/89A patent/AU625644B2/en not_active Expired
- 1989-12-18 NZ NZ231474A patent/NZ231474A/en unknown
-
1995
- 1995-09-21 HK HK152395A patent/HK152395A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE68908125D1 (de) | 1993-09-09 |
CA2003326A1 (en) | 1990-06-19 |
HK152395A (en) | 1995-09-29 |
US4882142A (en) | 1989-11-21 |
IL92373A (en) | 1995-08-31 |
EP0374501B1 (en) | 1993-08-04 |
KR0142907B1 (ko) | 1998-07-15 |
DK582789D0 (da) | 1989-11-20 |
PH26086A (en) | 1992-02-06 |
IE893714L (en) | 1990-06-19 |
CA2003326C (en) | 1999-01-19 |
JPH02237936A (ja) | 1990-09-20 |
PT92362B (pt) | 1995-09-12 |
EP0374501A1 (en) | 1990-06-27 |
DE68908125T2 (de) | 1994-03-03 |
DK175607B1 (da) | 2004-12-27 |
ZA898866B (en) | 1991-07-31 |
FI895516A0 (fi) | 1989-11-20 |
PT92362A (pt) | 1990-06-29 |
DK582789A (da) | 1990-06-20 |
JP2795934B2 (ja) | 1998-09-10 |
AU4544089A (en) | 1990-06-21 |
IE69049B1 (en) | 1996-08-07 |
NZ231474A (en) | 1992-06-25 |
AU625644B2 (en) | 1992-07-16 |
ATE92339T1 (de) | 1993-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900009080A (ko) | 골수 억제제 | |
US7097823B2 (en) | High dose radionuclide complexes for bone marrow suppression | |
CA2005880C (en) | Macrocyclic aminophosphonic acid complexes, their preparation formulations and use | |
US4898724A (en) | Organis amine phosphonic acid complexes for the treatment of calcific tumors | |
US7691985B2 (en) | Skeletal-targeted radiation to treat bone-associated pathologies | |
JP2003501488A5 (ko) | ||
US5064633A (en) | Macrocyclic aminophosphonic acid complexes, their formulations and use | |
JP2005516933A (ja) | 放射性医薬による骨髄炎の治療 | |
US5066478A (en) | Radio labeled organic amine phosphonic acid complexes for the treatment of calcific tumors | |
Liesmann et al. | Phase I evaluation of ICRF‐187 (NSC‐169780) in patients with advanced malignancy | |
KR880013576A (ko) | 골수억제 조성물 및 이의 용도 | |
EP1438076B1 (en) | Radiopharmaceutical agent for the treatment of early stage cancer | |
Edmonson et al. | Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas | |
Soloway et al. | 10B+ n,+[nB]+ 7Li (0.87 MeV)+ a (1.52 MeV). tn Table 1. | |
AU2002353865A1 (en) | Radiopharmaceutical agent for the treatment of early stage cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080328 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |